NexgenRx Inc.
NEGXF
$0.33
$0.0622.04%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.72% | 7.92% | 6.41% | 9.35% | 12.01% |
| Total Other Revenue | -33.74% | -38.77% | 54.04% | 9.68% | -10.80% |
| Total Revenue | 10.24% | 6.28% | 8.24% | 9.36% | 11.09% |
| Cost of Revenue | -16.87% | -14.56% | -6.20% | 2.88% | 5.80% |
| Gross Profit | 17.16% | 11.61% | 12.11% | 11.08% | 12.53% |
| SG&A Expenses | 6.64% | 5.62% | 1.18% | 1.12% | 4.20% |
| Depreciation & Amortization | -9.27% | -5.42% | -3.00% | -4.37% | -5.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.17% | 0.28% | -0.78% | 1.02% | 3.66% |
| Operating Income | 134.61% | 82.99% | 294.93% | 632.16% | 873.41% |
| Income Before Tax | 145.38% | 85.16% | 536.13% | 43,673.91% | 2,895.67% |
| Income Tax Expenses | 57.45% | 58.21% | 1,482.80% | 1,408.72% | 1,431.25% |
| Earnings from Continuing Operations | 199.25% | 102.53% | 443.65% | 4,242.44% | 1,124.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 199.25% | 102.53% | 443.65% | 4,242.44% | 1,124.09% |
| EBIT | 134.61% | 82.99% | 294.93% | 632.16% | 873.41% |
| EBITDA | 63.80% | 43.97% | 66.01% | 66.27% | 55.35% |
| EPS Basic | 249.06% | 124.00% | 6,450.00% | 418.52% | 270.97% |
| Normalized Basic EPS | 153.62% | 94.03% | 505.26% | 8,600.00% | 3,550.00% |
| EPS Diluted | 269.57% | 97.96% | 2,975.00% | 332.35% | 221.05% |
| Normalized Diluted EPS | 141.79% | 83.33% | 488.89% | 8,200.00% | 3,450.00% |
| Average Basic Shares Outstanding | 0.31% | 0.38% | 0.13% | 0.31% | 0.45% |
| Average Diluted Shares Outstanding | 4.79% | 6.12% | 5.87% | -0.28% | 0.16% |
| Dividend Per Share | 47.95% | 47.95% | 45.95% | -2.70% | -1.35% |
| Payout Ratio | -0.52% | -0.30% | -0.74% | 1.02% | 1.10% |